Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Erbitux Open-label Results For NSCLC Hardly Stellar

Sep 02 2008

• By Pamela Taulbee

Related Content

Erbitux Misses Primary Endpoint As First-Line Treatment In Phase III NSCLC Trial

Jul 12 2007

FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC

Jun 01 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window